Get the Stockscreener App
56.12
1.15%
0.64
Rhythm Pharmaceuticals Inc Stock (RYTM) Forecast
The Rhythm Pharmaceuticals Inc (RYTM) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $40.54, representing a -27.76% decrease from the current price of $56.12. The highest analyst price target is $42.35, and the lowest is $38.73.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month RYTM Price Target
Average 40.06
(-28.61% Downside)
Is Rhythm Pharmaceuticals Inc (RYTM) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 46.95 | Neutral |
| STOCH(9,6) | 24.13 | Neutral |
| STOCHRSI(14) | 47.16 | Neutral |
| MACD(12,26) | -0.6015 | Sell |
| ADX(14) | 21.46 | Neutral |
| William %R | -66.79 | Neutral |
| CCI(14) | -20.82 | Neutral |
Buy: 0
Sell: 1
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
56.06
Buy
|
56.29
Sell
|
| MA20 |
58.23
Sell
|
57.10
Sell
|
| MA50 |
56.14
Sell
|
56.02
Buy
|
| MA100 |
52.19
Buy
|
53.01
Buy
|
| MA200 |
46.94
Buy
|
48.10
Buy
|
Buy: 6
Sell: 4
Neutral: 0
Summary: Buy
According to our latest analysis, RYTM could be considered a Neutral, with 17 technical analysis indicators signaling 6 Buy signals, 5 signaling Sell signals and 6 Neutral signals. This suggests that investors should exercise caution when entering new positions on RYTM, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 46.95 indicates that RYTM is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 24.13 indicates that RYTM is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 47.16 indicates that RYTM is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 21.46 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -20.82 indicates that RYTM is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term RYTM price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Rhythm Pharmaceuticals Inc financial reports and earnings history, Rhythm Pharmaceuticals Inc (RYTM) stock could reach $60.18 by 2030, $89.84 by 2040 and $114.71 by 2050. See the projected annual prices until 2050 of the Rhythm Pharmaceuticals Inc stock below:
- Rhythm Pharmaceuticals Inc (RYTM) is expected to reach an average price of $82.21 in 2035, with a high prediction of $82.86 and a low estimate of $68.99. This indicates an $46.50% rise from the last recorded price of $56.12.
- Rhythm Pharmaceuticals Inc (RYTM) stock is projected to chart a bullish course in 2040, with an average price target of $88.34, representing an $57.41% surge from its current level. The forecast ranges from a conservative $85.23 to a sky-high $89.84.
- Our analysts predict Rhythm Pharmaceuticals Inc (RYTM) to jump 97.27% by 2045, soaring from $107.16 to an average price of $110.71, potentially reaching $117.36. While $107.16 is the low estimate, the potential upside is significant.
- Rhythm Pharmaceuticals Inc (RYTM) stock is expected to climb by 2050, reaching an average of $114.53, a $104.08% jump from its current level. However, a wide range of estimates exists, with high and low targets of $114.71 and $109.88, respectively, highlighting the market's uncertainty.
Rhythm Pharmaceuticals Inc Stock (RYTM) Year by Year Forecast
Rhythm Pharmaceuticals Inc Stock (RYTM) Price Forecast for 2025
Rhythm Pharmaceuticals Inc Stock (RYTM) is expected to reach an average price of $40.06 in 2025, with a high prediction of $50.14 and a low estimate of $29.98. This indicates an -28.61% fall from the last recorded price of $56.12.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $38.93 | $38.73 | $42.35 | -30.63% |
| February, 2025 | $34.25 | $34.05 | $39.07 | -38.96% |
| March, 2025 | $35.28 | $34.06 | $36.55 | -37.13% |
| April, 2025 | $32.01 | $29.98 | $38.12 | -42.97% |
| May, 2025 | $35.78 | $31.21 | $36.50 | -36.24% |
| June, 2025 | $35.82 | $34.58 | $37.96 | -36.18% |
| July, 2025 | $39.75 | $36.25 | $39.93 | -29.16% |
| August, 2025 | $38.60 | $38.59 | $43.35 | -31.22% |
| September, 2025 | $36.58 | $35.96 | $40.85 | -34.81% |
| October, 2025 | $47.75 | $35.75 | $49.05 | -14.91% |
| November, 2025 | $39.67 | $39.42 | $50.14 | -29.32% |
| December, 2025 | $39.32 | $38.64 | $44.55 | -29.93% |
Rhythm Pharmaceuticals Inc Stock (RYTM) Price Forecast for 2026
The predicted value for Rhythm Pharmaceuticals Inc (RYTM) in 2026 is set at an average of $46.47. Estimates vary from a peak of $61.85 to a trough of $31.09, indicating an -17.19% surge from the present price of $56.12.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $47.55 | $38.74 | $49.52 | -15.28% |
| February, 2026 | $47.07 | $46.04 | $52.61 | -16.12% |
| March, 2026 | $52.79 | $45.88 | $53.94 | -5.94% |
| April, 2026 | $45.90 | $45.41 | $61.85 | -18.20% |
| May, 2026 | $44.39 | $43.33 | $47.54 | -20.90% |
| June, 2026 | $40.20 | $38.00 | $45.11 | -28.36% |
| July, 2026 | $41.64 | $38.25 | $42.00 | -25.80% |
| August, 2026 | $38.30 | $37.41 | $42.17 | -31.76% |
| September, 2026 | $39.25 | $38.33 | $41.02 | -30.06% |
| October, 2026 | $33.53 | $32.56 | $39.68 | -40.26% |
| November, 2026 | $32.63 | $31.09 | $33.85 | -41.85% |
| December, 2026 | $32.86 | $31.85 | $33.81 | -41.45% |
Rhythm Pharmaceuticals Inc Stock (RYTM) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Rhythm Pharmaceuticals Inc (RYTM) is $34.93, with a high forecast of $45.85 and a low forecast of $24.01. This indicates an -37.76% decrease from the last price of $56.12.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $30.91 | $30.61 | $33.31 | -44.93% |
| February, 2027 | $30.33 | $30.03 | $34.18 | -45.95% |
| March, 2027 | $30.53 | $28.56 | $31.09 | -45.60% |
| April, 2027 | $29.34 | $28.64 | $32.62 | -47.72% |
| May, 2027 | $27.03 | $26.80 | $29.69 | -51.84% |
| June, 2027 | $29.86 | $26.51 | $29.94 | -46.79% |
| July, 2027 | $32.24 | $29.30 | $33.33 | -42.55% |
| August, 2027 | $28.86 | $28.63 | $33.20 | -48.57% |
| September, 2027 | $24.36 | $24.01 | $29.16 | -56.59% |
| October, 2027 | $25.07 | $24.26 | $26.18 | -55.33% |
| November, 2027 | $26.14 | $24.99 | $26.24 | -53.42% |
| December, 2027 | $43.21 | $25.76 | $45.85 | -23.01% |
Rhythm Pharmaceuticals Inc Stock (RYTM) Price Forecast for 2028
In 2028, Rhythm Pharmaceuticals Inc (RYTM) is projected to reach an average price of $47.77, with a high projection of $57.18 and a low estimate of $38.37. This indicates an -14.87% fall from the last price of $56.12.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $46.73 | $42.46 | $48.73 | -16.73% |
| February, 2028 | $46.16 | $41.67 | $52.58 | -17.75% |
| March, 2028 | $46.98 | $43.69 | $48.41 | -16.28% |
| April, 2028 | $46.76 | $43.45 | $50.32 | -16.68% |
| May, 2028 | $51.34 | $46.21 | $53.00 | -8.52% |
| June, 2028 | $51.58 | $49.86 | $57.18 | -8.09% |
| July, 2028 | $50.12 | $48.67 | $53.97 | -10.70% |
| August, 2028 | $42.10 | $41.66 | $50.40 | -24.98% |
| September, 2028 | $40.52 | $38.52 | $42.47 | -27.80% |
| October, 2028 | $39.44 | $39.12 | $44.39 | -29.72% |
| November, 2028 | $40.76 | $38.37 | $40.82 | -27.37% |
| December, 2028 | $39.53 | $39.46 | $43.00 | -29.57% |
Rhythm Pharmaceuticals Inc Stock (RYTM) Price Forecast for 2029
The 2029 price forecast for Rhythm Pharmaceuticals Inc Stock (RYTM) is $57.68 on average, with a high prediction of $76.80 and a low estimate of $38.57. This represents an +2.78% increase from the previous price of $56.12.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $41.03 | $38.57 | $41.28 | -26.89% |
| February, 2029 | $49.15 | $42.21 | $50.47 | -12.42% |
| March, 2029 | $48.40 | $47.73 | $51.66 | -13.75% |
| April, 2029 | $48.55 | $44.51 | $49.42 | -13.49% |
| May, 2029 | $52.18 | $44.97 | $53.46 | -7.01% |
| June, 2029 | $57.64 | $50.88 | $59.08 | +2.71% |
| July, 2029 | $69.94 | $56.52 | $74.25 | +24.63% |
| August, 2029 | $68.24 | $63.25 | $72.02 | +21.60% |
| September, 2029 | $69.42 | $67.68 | $76.80 | +23.69% |
| October, 2029 | $64.96 | $62.07 | $71.63 | +15.76% |
| November, 2029 | $62.55 | $61.46 | $68.19 | +11.45% |
| December, 2029 | $56.89 | $55.24 | $66.83 | +1.37% |
Rhythm Pharmaceuticals Inc Stock (RYTM) Price Forecast for 2030
Rhythm Pharmaceuticals Inc Stock (RYTM) is expected to reach an average price of $53.57 in 2030, with a high forecast of $60.18 and a low forecast of $46.96. This signifies an -4.55% decrease from the last price of $56.12.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $53.72 | $53.25 | $60.18 | -4.27% |
| February, 2030 | $52.65 | $52.00 | $54.99 | -6.18% |
| March, 2030 | $51.08 | $49.67 | $53.40 | -8.97% |
| April, 2030 | $54.37 | $50.33 | $56.30 | -3.11% |
| May, 2030 | $53.96 | $52.16 | $57.23 | -3.85% |
| June, 2030 | $54.25 | $51.48 | $57.21 | -3.34% |
| July, 2030 | $54.86 | $52.59 | $55.56 | -2.24% |
| August, 2030 | $56.52 | $54.61 | $58.88 | +0.72% |
| September, 2030 | $54.16 | $53.45 | $57.88 | -3.49% |
| October, 2030 | $51.56 | $50.83 | $55.12 | -8.12% |
| November, 2030 | $47.87 | $46.96 | $55.05 | -14.71% |
| December, 2030 | $48.49 | $46.98 | $50.10 | -13.60% |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):